ProQR Therapeutics N.V. (PRQR) News
Follow ProQR Therapeutics N.V. (PRQR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 20 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Weekly Recap: AX-0811 clinical trial start and ProQR AI leadership hires
ProQR Therapeutics N.V. (NASDAQ:PRQR) is fast-tracking AI-discovered AX-0811 into clinical trials with target-engagement data due in early Jan 2027 while advancing AX-0422 and AX-2911 toward the clinic, bolstered by Gink
NEWS | Sep 28, 2026, 11:04 AM UTC
L
ProQR Therapeutics N.V. (PRQR) Names Chief Data & AI Officer; Adds AI Advisor to Board
ProQR appointed Chris Hart as Chief Data and AI Officer and added Hugging Face co-founder Thomas Wolf to its Board as strategic AI advisor, aiming to scale AI across Axiomer discovery and development.Material DetailsCont
NEWS | Sep 23, 2026, 12:04 PM UTC
L
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. NASDAQ:PRQR (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on i
NEWS | Sep 23, 2026, 12:03 PM UTC
L
ProQR Therapeutics: Thomas Wolf to Join the Bd of Directors as Strategic AI Advisor >PRQR
ProQR Therapeutics: Thomas Wolf to Join the Bd of Directors as Strategic AI Advisor >PRQR
NEWS | Sep 23, 2026, 12:00 PM UTC
L
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer
NEWS | Sep 23, 2026, 12:00 PM UTC
L
PRQR - ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
PRQR - ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
NEWS | Sep 23, 2026, 12:00 PM UTC
L
ProQR dosed first participant in Phase 1 AX-0811 study
ProQR Therapeutics N.V. announced the first participant was dosed in its Phase 1 study of AX-0811, alongside a Virtual Investor and Analyst Educational Event scheduled for September 30, 2026.
EQUITY | Sep 09, 2026, 12:01 PM UTC
L
ProQR announces first participant dosed in Phase 1 of AX-0811
ProQR says it has dosed the first participant in its Phase 1 study of AX-0811.
EQUITY | Sep 09, 2026, 12:00 PM UTC
L
ProQR to Participate in Upcoming Investor Conferences in September 2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. NASDAQ:PRQR (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on i
EQUITY | Sep 02, 2026, 12:07 PM UTC
L
PRQR to participate in investor conferences in September 2026
ProQR says it will participate in upcoming investor conferences in September 2026.
EQUITY | Sep 02, 2026, 12:00 PM UTC
L
BAML initiates PRQR at Buy with $8 target
BAML initiates PRQR at Buy with an $8 price target, according to the raw feed item; no additional catalyst or timing detail was supplied.
EQUITY | Aug 20, 2026, 01:05 PM UTC
H
ProQR Therapeutics initiated with Buy rating and $8 target by BofA
BofA analyst Alec Stranahan initiated coverage of ProQR Therapeutics with a Buy rating and a $8 price target, citing AX-0810 as first human validation of Axiomer and dose-dependent bile acid activity including up to an e
EQUITY | Aug 20, 2026, 12:55 PM UTC
H
ProQR Therapeutics: BofA initiates coverage with Buy, $8 target
BofA’s Alec Stranahan initiated coverage of ProQR Therapeutics with a Buy rating and a $8 price target, citing AX-0810 as first human validation of Axiomer and dose-dependent bile acid activity.
EQUITY | Aug 20, 2026, 12:28 PM UTC
M
PRQR initiates Buy at BofA Securities with $8.00 target
BofA Securities initiates coverage of PRQR with a Buy rating and an $8.00 price target.
EQUITY | Aug 20, 2026, 11:56 AM UTC
H
ProQR reports Q2 2026 operating and financial results
ProQR (PRQR) announces its second quarter 2026 operating and financial results, with no additional figures or guidance details provided in the alert.
EQUITY | Aug 13, 2026, 11:00 AM UTC
M
Insiders Buy BSX, HOG, HUN, PRQR, ACI Shares
Insiders purchase shares of various companies
EQUITY | Aug 03, 2026, 09:52 PM UTC
M
ProQR Therapeutics shares are trading higher after Evercore ISI Group maintained its Outperform rating on the stock and raised its price tar
ProQR Therapeutics shares are trading higher after Evercore ISI Group maintained its Outperform rating on the stock and raised its price target from $5 to $6.
EQUITY | Jun 29, 2026, 05:44 PM UTC
M
Evercore ISI Group Maintains Outperform on ProQR Therapeutics, Raises Price Target to $6
Evercore ISI Group analyst Gavin Clark-Gartner maintains ProQR Therapeutics (NASDAQ: PRQR ) with a Outperform and raises the price target from $5 to $6.
EQUITY | Jun 29, 2026, 03:00 PM UTC
M
PRQR Prices $50M Offering
ProQR prices $50.0 million underwritten registered direct offering and concurrent private placement
EQUITY | Jun 25, 2026, 10:35 AM UTC
H
PRQR: Reports Positive Phase 1 Data
ProQR announces positive phase 1 target engagement data for AX-0810, validating the Axiomer RNA editing platform
EQUITY | Jun 25, 2026, 10:25 AM UTC